Current Report Filing (8-k)
September 06 2019 - 5:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 24, 2019
Hypertension
Diagnostics, Inc.
(Exact name of registrant as specified in
its charter)
|
Minnesota
|
|
000-24635
|
|
41-1618036
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
IRS Employer
Identification No.)
|
|
550 Highway 7 East, Unit 316
Richmond Hill, Ontario, Canada
|
|
L4B
3Z4
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(407) 449-6151
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address,
if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
Not applicable
|
|
Not applicable
|
|
Not applicable
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [_]
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 5.01 Changes in Control of Registrant
On May 24th ,
2019, Mr. Liangjian Peng, through a Stock Purchase Agreement, received 3 Million Preferred shares controlling shares with voting
rights and conversion of 1:1000 common shares of the company stock.
Item 8.01 Other Events
Hypertension Diagnostics,
Inc. intends to file the last two annual reports in an effort to get current with the OTC Markets and for full disclosure to
stockholders of company business.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
Hypertension Diagnostics, Inc.
|
|
|
|
|
Date: September 6, 2019
|
By: /s/ Liangjian Peng
|
|
|
Liangjian Peng
|
|
|
Chief Executive Officer
|
Hypertension Diagnositc (CE) (USOTC:HDII)
Historical Stock Chart
From Nov 2024 to Dec 2024
Hypertension Diagnositc (CE) (USOTC:HDII)
Historical Stock Chart
From Dec 2023 to Dec 2024
